Generative AI Could Reorder Cardiovascular Care, but Bias Can Travel With It
Generative artificial intelligence is moving quickly into cardiovascular medicine, and its promise is large enough to change how clinicians triage, counsel, and connect with patients. A JACC Advances review by Kulkarni and Visweswaran frames that promise around equity, arguing that the same tools capable of widening access to specialty care can also reproduce the inequities already embedded in health systems, data pipelines, and clinical workflows.
The central problem is not abstract. When a model learns from unevenly sampled populations, noisy labels, or health records shaped by unequal access, it can reinforce the very gaps clinicians are trying to close. In cardiovascular medicine, those gaps matter at every step: who gets referred, who gets labeled with disease, who is seen in specialty clinic, and who is heard when symptoms are subtle or atypical. A model trained on incomplete reality can only mirror that incompleteness unless developers build safeguards into the system from the start.
Representation Bias Can Distort Who Benefits From the Model
The review places representation bias near the center of the equity discussion. If certain racial, ethnic, language, age, sex, disability, or socioeconomic groups are underrepresented in training data, the resulting system may work best for the populations that were already easiest to capture in the electronic record. In cardiovascular care, that can affect risk estimation, symptom interpretation, message generation, and recommendations that depend on prior encounters.
Representation problems do not only appear in training. They also emerge when deployment settings differ from the environment where the model was developed. A model that performed well in one health system can behave differently in another if the patient mix, documentation style, insurance structure, or referral patterns change. In practice, this means the apparent sophistication of generative AI can conceal a narrow clinical worldview unless developers actively widen the data sources and evaluate performance in the populations most likely to be missed.
Measurement, Labeling, and Deployment Bias Shape Clinical Output
The review also identifies measurement bias and labeling bias as major threats. Cardiovascular disease is often encoded in imperfect ways: diagnoses may depend on access to testing, documentation habits may vary by clinician, and outcome labels may reflect health care contact more than biologic truth. A patient with less access to care may appear healthier in the record simply because fewer tests were ordered or fewer diagnoses were recorded.
Generative models are especially vulnerable when labels are treated as ground truth rather than as artifacts of the system that produced them. A language model generating patient education material, for example, may reproduce clinical language that is accurate but inaccessible, or it may recommend next steps that assume resources the patient does not have. The problem deepens at deployment, where a seemingly neutral tool can be used in a clinic workflow that already privileges time, language, digital literacy, and insurance status. In that setting, the model may not create inequity, but it can quietly amplify it.
A model can be technically correct and still be clinically unfair.
Why Context Matters as Much as Code
The review argues that equitable generative AI requires more than technical tuning. It demands contextualization—the ability to account for social, clinical, and structural conditions that shape cardiovascular risk and care delivery. Patients do not live inside a clean data table. They live with transportation barriers, mistrust, housing instability, language discordance, limited broadband, and competing priorities that affect whether a recommendation can be followed.
That is why the authors propose design principles built around representation and contextualization, along with transparency, accountability, and community engagement. Transparency makes model behavior easier to inspect. Accountability creates a chain of responsibility for errors and inequities. Community engagement brings patients and communities into the process rather than treating them as passive recipients of algorithmic care. Each principle addresses a different point of failure, and each becomes more important as generative systems move from back-end experimentation into bedside use.
Equity Tools Must Be Built Into the AI Lifecycle
The review advances a framework that extends across the full AI lifecycle. Equity cannot be added after deployment as a public relations correction. It must be built into data collection, model design, validation, implementation, monitoring, and recalibration. The authors call for operational strategies of digital equity and continuous recalibration, a practical recognition that model behavior drifts as populations, documentation patterns, and workflows change.
In cardiovascular medicine, that lifecycle approach has direct consequences. If a language model is used to draft discharge instructions after heart failure admission, the readability, language access, and cultural fit of those instructions affect whether the plan survives beyond the hospital walls. If generative AI helps schedule specialty follow-up or summarize symptoms for a triage nurse, the system must be checked for unequal failure modes across groups. A tool that works for patients with stable internet access may fail for patients who rely on shared devices, limited data plans, or translation support.
Access, Literacy, and Trial Participation Are Real Opportunities
The review does not cast generative AI as only a risk. It also identifies concrete ways the technology could improve care if deployed responsibly. One pathway is improved access to specialty care, especially when generative tools help patients navigate questions, prepare for visits, or understand what cardiology care involves. Another is better health literacy, because patient-facing models can translate complex cardiovascular concepts into clearer language and more actionable instructions.
Broader clinical trial participation is another potential gain. Cardiovascular research has long struggled with underrepresentation, and generative tools could help identify eligible patients, explain trial procedures in plain language, and reduce administrative friction that blocks enrollment. Even there, the same caution applies: a tool designed to broaden participation must not end up selecting only those already closest to care. Access gains are meaningful only if they reach the patients who have historically been excluded.
Governance Will Decide Whether the Technology Narrows or Widens Gaps
The review closes by pressing for governance and oversight across the full lifespan of generative AI models. Oversight is not an optional add-on. It is the only way to detect when a model begins to drift, when performance differs by subgroup, or when a clinical workflow starts depending on an unexamined output.
That governance burden belongs to institutions, developers, clinicians, and communities together. Cardiovascular medicine will not benefit from generative AI simply because the tools are new or fast. It will benefit only if the systems are built to expose bias, measure impact, and allow correction before inequity becomes automated into routine care. The remaining clinical question is not whether these models will enter cardiovascular practice; they already are. The harder question is whether the field will audit them with enough rigor to keep their benefits from landing unevenly.